Please assess the completion status of the following clinical trial:

Trial Title: FET-PET/MRI for Surgical Assessment of Pediatric Brain Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient must have a known or suspected primary brain tumor with a non-enhancing component with planned standard of care surgical resection. Patients with newly diagnosed or recurrent brain tumors are eligible.~2. Tumors with non-enhancing regions will be defined as T2/FLAIR hyperintensity extending at least 0.5 cm beyond areas of enhancement as assessed by MRI.~3. Patient must be 18 years of age or younger at the time of study enrollment.~4. Patient must have measurable disease defined as tumor measurable in two perpendicular dimensions on MRI greater than 1 cm.~5. Patient must have a life expectancy greater than 8 weeks.~6. Patient must be able to undergo FET-PET/MRI without sedation.~7. Females with childbearing potential must have a negative urine β-hCG test on the day of procedure or a serum hCG test within 48 hours prior to the administration FET. Females who have not reached menarche will not require pregnancy testing.~Exclusion Criteria:~1. Patient must not be receiving an investigational or standard of care anti-cancer drug within 6 months prior to the FET-PET/MRI study.~2. Patient must not have received radiation therapy within the past 6 months.~3. Patient must not have a contraindication to contrast-enhanced MRI (e.g. renal insufficiency, incompatible implant).~4. Patient must not be pregnant or breast feeding.~5. Patient must not have been treated for another cancer within 5 years with the exception of cutaneous basal cell carcinoma or squamous cell carcinoma.~6. Patients must not have a history of brain metastases.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- FET-PET/MRI (Type: EXPERIMENTAL): O-(2-\[F-18\]FET)-L-tyrosine (FET) for brain PET/MRI

Based on this trial design, predict the completion outcome and termination type (if applicable).